Nimotuzumab

China approves use of Cuban drug against head and neck cancer

Published on: February 5, 2024
13:51

Beijing, Feb 5 (Prensa Latina) China on Monday approved the registration of Nimotuzumab, a Cuban humanized monoclonal antibody to treat head and neck cancer, a new milestone in biotechnological cooperation between the two countries.

China praises biotechnology cooperation with Cuba

Published on: August 7, 2023
10:46

Beijing, Aug 7 (Prensa Latina) Bai Xianhong, director of the Chinese-Cuban joint venture Biotech Pharma (BPL), praised the biotechnological cooperation between the two nations and its positive impact on his country.

Cuban Nimotuzumab drug to get registered in China

Published on: June 20, 2023
16:12

Beijing, Jun 20 (Prensa Latina) Cuba's humanized monoclonal antibody Nimotuzumab got registered in China to treat pancreatic cancer, since it benefits patients and commercialization possibilities in China and other foreign markets.

Cuba: CITMA awards CIM for effective monoclonal antibody Nimotuzumab

Published on: January 11, 2023
14:44

Havana, Jan 11 (Prensa Latina) The Science, Technology and Environment Ministry (CITMA) awarded Cuba's Center for Molecular Immunology (CIM) for research on the humanized monoclonal antibody Nimotuzumab.

NEWS

Nimotuzumab

China approves use of Cuban drug against head and neck cancer

China praises biotechnology cooperation with Cuba

Cuban Nimotuzumab drug to get registered in China

Cuba: CITMA awards CIM for effective monoclonal antibody Nimotuzumab

LATEST NEWS